Sanofi/GSK announce delay in COVID-19 vaccine project

- Advertisement -

An experimental COVID-19 vaccine developed by Sanofi and Britain’s GlaxoSmithKline showed an insufficient immune response in clinical trial results, the French drugmaker said on Friday, a blow to efforts to fight the pandemic.

The two companies said they planned to launch another study next year, hoping to come up with a more effective vaccine by the end of 2021.

Friday’s results, Sanofi said, showed “an immune response comparable to patients who recovered from COVID-19 in adults aged 18 to 49 years, but a low immune response in older adults likely due to an insufficient concentration of the antigen.”

READ  Bahrain: COVID-19 vaccinations generate wide interest

Phase III studies were expected to start this month.



- Advertisement -

Related Articles

Back to top button